Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corp (Nasdaq: LUNG) delivers innovative minimally invasive solutions for severe lung diseases, including its FDA-cleared Zephyr Valve system. This news hub provides essential updates for stakeholders tracking medical advancements and corporate developments in interventional pulmonology.
Access real-time updates on clinical trial milestones, regulatory approvals, and strategic partnerships that shape treatment paradigms for emphysema and COPD. Our curated collection features earnings reports, product launch details, and peer-reviewed research findings - all vital for understanding Pulmonx's market position.
Key content includes analysis of pulmonary treatment innovations, global commercialization efforts, and financial performance metrics. Investors and healthcare professionals will find timely information on FDA submissions, international expansion, and clinical outcome studies that demonstrate improved patient quality of life.
Bookmark this page for centralized access to Pulmonx's latest advancements in bronchoscopic lung volume reduction technology. Stay informed about developments that impact both respiratory care standards and long-term corporate growth strategies.
Pulmonx (NASDAQ: LUNG) announced a management transition and preliminary third quarter 2025 revenue on October 27, 2025. Glen French is reappointed President and CEO effective immediately; Derrick Sung will become COO and CFO effective November 3, 2025. Two executives, Steve Williamson and Mehul Joshi, resigned and will serve as advisors through December 1, 2025. The company reported preliminary, unaudited Q3 2025 revenue of approximately $21.5 million. Third quarter 2025 financial results and a conference call were rescheduled for November 12, 2025 at 1:30 p.m. PT / 4:30 p.m. ET. The revenue figure is preliminary and subject to revision when full results are released.
Pulmonx (Nasdaq: LUNG) will report third quarter 2025 financial results after market close on Wednesday, October 29, 2025.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day. Interested parties must register online to receive dial‑in details and a personal PIN. A live and archived webcast will be available in the Investors section at https://investors.pulmonx.com/.
Pulmonx (NASDAQ:LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4 at 1:30 PM PT in Boston, with a webcast available. Additionally, management will attend the Lake Street Best Ideas Growth Conference on September 11 in New York for one-on-one meetings. Investors can access the Wells Fargo fireside chat webcast through Pulmonx's investor relations website.
Pulmonx (Nasdaq: LUNG) reported its Q2 2025 financial results, achieving total revenue of $23.9 million, representing a 15% year-over-year increase. The company's performance was driven by strong international growth of 32% ($9.1 million), while U.S. revenue grew 6% ($14.7 million).
The company maintained a gross margin of 72% but reported a net loss of $15.2 million ($0.38 per share). Due to slower-than-expected U.S. revenue conversion, Pulmonx revised its full-year 2025 guidance down to $90-92 million from the previous $96-98 million forecast. Operating expenses are now expected to be $128-130 million, reduced from prior guidance of $133-135 million.
Pulmonx (NASDAQ:LUNG), a company specializing in minimally invasive lung disease treatments, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation is scheduled for August 12, 2025, at 7:00 AM PT / 10:00 AM ET in Boston.
Investors and interested parties can access both the live presentation and archived webcast through the investor relations section of Pulmonx's website at investors.pulmonx.com.
Pulmonx (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has scheduled its Q2 2025 financial results announcement for July 30, 2025, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live and archived webcast through the company's investor relations website.
Pulmonx Corporation (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in the Goldman Sachs 46th Annual Global Health Care Conference. The presentation is scheduled for June 11, 2025, at 7:00 AM PT / 10:00 AM ET in Miami. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The presentation is scheduled for Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET in Las Vegas. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.pulmonx.com.
Pulmonx (Nasdaq: LUNG) reported strong Q1 2025 financial results, achieving worldwide revenue of $22.5 million, marking a 20% increase year-over-year. The company's performance was driven by both domestic and international growth, with U.S. revenue reaching $14.2 million (11% increase) and international revenue hitting $8.3 million (39% increase).
Key financial metrics include:
- Gross margin of 73%
- Operating expenses of $30.9 million
- Net loss of $14.4 million ($0.36 per share)
- Cash and equivalents totaling $88.7 million
The company reaffirmed its 2025 revenue guidance of $96-98 million and expects a gross margin of approximately 74%. Operating expenses are projected between $133-135 million, including $22 million in stock-based compensation. The U.S. Department of Justice has declined to intervene in a case against Pulmonx and concluded its civil investigative demand.
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for lung disease, has announced it will release its first quarter 2025 financial results after market close on Wednesday, April 30, 2025.
The company will host a conference call with management to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access both the live and archived webcast of the earnings call through the investor relations section of Pulmonx's website.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
